Gamma-polyglutamic acid-coated vectors for effective and safe gene therapy

Journal of Controlled Release : Official Journal of the Controlled Release Society
Tomoaki KurosakiHitoshi Sasaki

Abstract

In the present study, we developed some novel gene delivery vectors, coated cationic complexes with gamma-polyglutamic acid (gamma-PGA) for effective and safe gene therapy. Cationic complexes were constructed with pDNA and cationic vectors, such as poly-L-arginine hydrochloride (PLA), poly-L-lysine hydrobromide (PLL), N-[1-(2, 3-dioleyloxy) propyl]-N, N, N-trimethylammonium chloride (DOTMA)-cholesterol (Chol) liposomes, and DOTMA-dioleylphosphatidylethanolamine (DOPE) liposomes. The cationic complexes showed high gene expression with strong cytotoxicity in melanoma B16-F10 cells. The cationic complexes were also strongly toxic to erythrocytes. On the other hand, the gamma-PGA was able to coat all cationic complexes and form stable nano-sized particles with negative charges. These gamma-PGA-coated complexes had high gene expression without cytotoxicity and toxicities to the erythrocytes. In in vivo transfection experiments, polyplexes showed high transfection efficiency over 10(5) RLU/g in the lung tissue after intravenous injection, although gamma-PGA-coated polyplexes showed a high value in the spleen. High transfection efficiency in lipoplexes and gamma-PGA-coated lipoplexes was observed in the spleen and lung. Thus, gamma-PG...Continue Reading

References

Nov 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·P L FelgnerM Danielsen
Aug 1, 1995·Proceedings of the National Academy of Sciences of the United States of America·O BoussifJ P Behr
Sep 19, 1998·Journal of Controlled Release : Official Journal of the Controlled Release Society·C W PoutonS H Moss
Mar 4, 2000·Journal of Controlled Release : Official Journal of the Controlled Release Society·L DekieL W Seymour
Mar 30, 2000·The Journal of Gene Medicine·R KircheisE Wagner
Nov 30, 2000·The Journal of Peptide Research : Official Journal of the American Peptide Society·D J MitchellJ B Rothbard
Apr 20, 2002·Drug Discovery Today·Manfred Ogris, Ernst Wagner
Apr 8, 2003·Current Medicinal Chemistry·Aaron HirkoJeffrey A Hughes
Apr 28, 2004·Biomaterials·Valeria PiddubnyakZdzisław Krawczyk
Sep 15, 2004·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Feng LiuLeaf Huang
May 10, 2005·Journal of Controlled Release : Official Journal of the Controlled Release Society·Seung Eun CookChong Su Cho
Sep 27, 2005·Journal of Controlled Release : Official Journal of the Controlled Release Society·Yoshiyuki HattoriMitsuru Hashida
Apr 6, 2007·The AAPS Journal·Xiang GaoDexi Liu
Apr 6, 2007·Biological & Pharmaceutical Bulletin·Lap Thi NguyenHiroshi Kiwada
Aug 28, 2007·The Journal of Gene Medicine·Michael L EdelsteinJo Wixon
Jan 16, 2008·Infection and Immunity·Marjorie D SutherlandThomas R Kozel
May 1, 2008·Journal of Drug Targeting·Tomoko ItoYoshiyuki Koyama
Aug 9, 2008·International Journal of Pharmaceutics·Megumi MatsumotoHitoshi Sasaki
Feb 3, 2009·Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Société Canadienne Des Sciences Pharmaceutiques·Tomoaki KurosakiHitoshi Sasaki

❮ Previous
Next ❯

Citations

Nov 6, 2013·Biological & Pharmaceutical Bulletin·Kosuke KandaHitoshi Sasaki
Nov 6, 2013·Biological & Pharmaceutical Bulletin·Tomoaki KurosakiHitoshi Sasaki
Jan 23, 2014·Journal of Materials Science. Materials in Medicine·K IsakssonB Tingstedt
Apr 19, 2013·Journal of Drug Targeting·Yoshiyuki HattoriYoshie Maitani
Jan 17, 2012·Expert Opinion on Drug Delivery·José Vicente González-AramundizNoemi Csaba
Jul 23, 2011·Journal of Pharmaceutical Sciences·Tomoaki KurosakiHitoshi Sasaki
Sep 27, 2012·Colloids and Surfaces. B, Biointerfaces·Yung-Chih Kuo, Yu-Hsuan Chang
May 24, 2011·Journal of Controlled Release : Official Journal of the Controlled Release Society·Ethlinn V B van GaalEnrico Mastrobattista
Jan 25, 2014·Scientific Reports·Yoko Endo-TakahashiYukihiko Aramaki
Dec 9, 2014·Cancer Biology & Therapy·Paulina WyrozumskaAleksander F Sikorski
Aug 9, 2011·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Sushil Kumar TripathiK C Gupta
Oct 8, 2014·International Journal of Pharmaceutics·Yoshiyuki HattoriEtsuo Yonemochi
Jul 30, 2015·Biomaterials Science·Zhe YangXintao Shuai
Jan 4, 2017·Journal of Drug Targeting·Marie IwanagaHitoshi Sasaki
Apr 6, 2017·Macromolecular Bioscience·Amaya Niño-ParienteMaría J Vicent
Nov 28, 2013·Journal of Materials Chemistry. B, Materials for Biology and Medicine·Pankaj GargJong Hoon Chung
Jun 4, 2013·Biological & Pharmaceutical Bulletin·Yukinobu KodamaHitoshi Sasaki
Jun 21, 2015·Journal of Materials Chemistry. B, Materials for Biology and Medicine·Tingbin ZhangXing-Jie Liang
Mar 2, 2021·Biological & Pharmaceutical Bulletin·Toshie TanakaTakahiro Mukai
May 16, 2021·Advanced Materials·Zhen ZhangYouqing Shen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Antibodies: Agglutination

Antibody-mediated agglutination is the clumping of cells in the presence of antibody, which binds multiple cells together. This enhances the clearance of pathogens. Find the latest research on antibody-mediated agglutination here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.